<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313180</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0225</org_study_id>
    <secondary_id>2016-003403-66</secondary_id>
    <nct_id>NCT03313180</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis.</brief_title>
  <official_title>An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to assess long term safety of treatment with oral nintedanib in
      patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of overall adverse events over the course of this extension trial</measure>
    <time_frame>Up to 34 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Lung Diseases, Interstitial</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Administered twice daily</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>OVEF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who completed the parent trial 1199.214 per protocol and did not permanently
             discontinue blinded treatment

          -  Signed and dated written informed consent in accordance with International Conference
             on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to
             admission to the trial

          -  Women of childbearing potential must be ready and able to use highly effective methods
             of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per
             year when used consistently and correctly as well as one barrier method for 28 days
             prior to nintedanib treatment initiation, during the trial and for 3 months after last
             intake of nintedanib.

          -  Further inclusion criteria apply

        Exclusion Criteria:

          -  Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) &gt; 3 x Upper Limit of
             Normal (ULN)

          -  Bilirubin &gt; 2 x ULN

          -  Creatinine clearance &lt;30 mL/min calculated by Cockcroft-Gault formula.

          -  Clinically relevant anaemia at investigators discretion.

          -  Bleeding risk, any of the following

               -  Known genetic predisposition to bleeding according to the judgement of the
                  investigator

               -  Patients who require

                    -  Fibrinolysis, full-dose therapeutic anticoagulation

                    -  High dose antiplatelet therapy.

               -  Hemorrhagic central nervous system (CNS) event after completion of the parent
                  trial 1199.214

               -  Any of the following after last treatment of 1199.214:

                    -  Haemoptysis or haematuria

                    -  Active gastro-intestinal bleeding or Gastrointestinal (GI) - ulcers

                    -  Gastric antral vascular ectasia (GAVE)

                    -  Major injury or surgery

               -  Coagulation parameters: International normalised ratio (INR) &gt;2, prolongation of
                  prothrombin time (PT) and partial thromboplastin time (PTT) by &gt;1.5 x ULN at
                  Visit 1.

          -  New major thrombo-embolic events developed after completion of the parent trial
             1199.214:

               -  Stroke;

               -  Deep vein thrombosis;

               -  Pulmonary embolism;

               -  Myocardial infarction.

          -  Major surgery performed within the next 3 months

          -  Time period &gt; 12 weeks between last drug intake in 1199.214 and Visit 2 of this trial.

          -  Usage of any investigational drug after completion of the parent trial 1199.214 or
             planned usage of an investigational drug during the course of this trial.

          -  A disease or condition which may put the patient at risk because of participation in
             this trial (e.g. clinically relevant intestinal pseudoobstruction) or limit the
             patient's ability to participate in this trial

          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,
             makes them an unreliable trial subject or unlikely to complete the trial

          -  Known hypersensitivity to the trial medication or its components (i.e. soya lecithin).

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial

          -  Previous enrolment in this trial

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Highland</last_name>
      <phone>+001 (216) 445-5429</phone>
      <email>highlak@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Lancaster</last_name>
      <phone>+001 (615) 343-7068</phone>
      <email>lisa.lancaster@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APRILLUS</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1046AAQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Mannucci Walter</last_name>
      <phone>+54 11 4951 2763</phone>
      <email>walter_mannucci@yahoo.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Stevens</last_name>
      <phone>+ 61 392313983</phone>
      <email>wendy@svhrheum.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Reg. de Concepción &quot;Dr. G. Grant Benavente&quot;</name>
      <address>
        <city>Concepción</city>
        <zip>4070038</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxana Italia de Lourdes Maturana Rozas</last_name>
      <phone>+56 41 268 7724 / 272 2686</phone>
      <email>rmaturan@udec.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lidwine Wemeau</last_name>
      <phone>+33 (0)3 20 44 59 48</phone>
      <email>lidwine.wemeau@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Bewig</last_name>
      <phone>+49 (431) 50022205</phone>
      <email>bbewig@1med.uni-kiel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Cutolo</last_name>
      <phone>+39 (010) 3537994</phone>
      <email>cutolosecretary@unige.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria-Universita' La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Riccieri</last_name>
      <phone>+39 (06) 49974641</phone>
      <email>valeria.riccieri@uniroma1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum (LUMC)</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.K. de Vries - Bouwstra</last_name>
      <phone>+31(0)71 526 9111</phone>
      <email>J.K.de_Vries-Bouwstra@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madelon Vonk</last_name>
      <phone>+31(0)24-3611111</phone>
      <email>Madelon.Vonk@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EMED, Center of Medical Services,Private Prac,Rzeszow</name>
      <address>
        <city>Rzeszow</city>
        <zip>35205</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Denton</last_name>
      <phone>0207 830 2267</phone>
      <email>c.denton@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Greece</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

